Semaglutide vs. Tirzepatide
A neutral comparison of two FDA-approved prescription GLP-1 medications — what each is, their brand names, and how access differs across telehealth. Not a claim about results.
By The Peptide Samples Desk · 6 min read · Updated 2026-06-14
Find your match.
Answer two quick questions — we'll point you to the gummy that fits and this week's best deal.
Semaglutide and tirzepatide are the two GLP-1-class prescription medications people most often compare. Unlike most peptides, both are FDA-approved finished drugs — so this comparison focuses on what each is, their brand names, and how access and pricing differ across telehealth, not on results.
We make no claim about which produces more of any outcome. Both are prescription medications, and which (if either) is appropriate is a clinical decision a licensed provider makes.
For adults 18+. This article is educational and is not medical advice. Both require a consultation with a licensed provider. Compounded versions are not FDA-approved finished products and their availability and rules change. Statements have not been evaluated by the FDA.
The short version
- Both are FDA-approved prescription medications — a key difference from gray-market peptides like BPC-157.
- Semaglutide is sold under brand names Ozempic and Wegovy (and oral Rybelsus); tirzepatide is sold as Mounjaro and Zepbound.
- Tirzepatide is a dual GIP/GLP-1 receptor agonist; semaglutide is a GLP-1 receptor agonist — we state the mechanism class, not comparative outcomes.
- Both require a licensed provider; manufacturer-direct programs (NovoCare, LillyDirect) and telehealth (Eden, Henry, Ivim) are the legitimate routes.
- Compounded versions exist and are not FDA-approved finished products; availability and rules change — confirm what you're getting and the all-in price at the source.
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Class | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| FDA status | FDA-approved prescription medication | FDA-approved prescription medication |
| Brand names | Ozempic, Wegovy, Rybelsus (oral) | Mounjaro, Zepbound |
| Maker-direct | NovoCare (Novo Nordisk) | LillyDirect (Eli Lilly) |
| Telehealth access | Eden, Henry Meds, Ivim (brand or compounded) | Eden, Henry Meds, Ivim (brand or compounded) |
| Compounded? | Exists; not FDA-approved finished product | Exists; not FDA-approved finished product |
Semaglutide vs. tirzepatide, on class, brands, and access — facts, not comparative results. Pricing is provider/manufacturer-attributed; verify at the source.
Find your match
30-sec finder
Question 1 of 5
What are you here to look into?
Both are FDA-approved — that's the headline
Unlike most compounds covered on this site, both semaglutide and tirzepatide are FDA-approved prescription medications. Semaglutide is sold under the brand names Ozempic and Wegovy (and oral Rybelsus); tirzepatide is sold as Mounjaro and Zepbound. Mechanistically, semaglutide is a GLP-1 receptor agonist and tirzepatide is a dual GIP/GLP-1 receptor agonist — we state the class, not a comparison of outcomes, which is a clinical matter.
The real difference for a reader: access and what you're getting
Both require a licensed provider. The legitimate routes are manufacturer-direct — NovoCare (Novo Nordisk) for semaglutide, LillyDirect (Eli Lilly) for tirzepatide — and telehealth providers like Eden, Henry Meds, and Ivim, which may offer brand-name or compounded versions. The crucial thing to confirm is whether you're getting an FDA-approved brand drug or a compounded version (not an FDA-approved finished product), plus the all-in monthly cost. We cover this in GLP-1 peptide providers.
How to think about it
We won't say one is 'better' — that's a clinical decision after an evaluation, based on your situation, history, and what your provider recommends. For a reader, the useful comparison is brand vs. compounded and total transparent cost, through a licensed provider. See the GLP-1 peptides guide for the category basics.
Questions, answered
What's the difference between semaglutide and tirzepatide?
Both are FDA-approved prescription GLP-1-class medications. Semaglutide (Ozempic, Wegovy, Rybelsus) is a GLP-1 receptor agonist; tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist. We state the class, not comparative outcomes — which is appropriate is a clinical decision. This is educational, not medical advice.
Are they available without a prescription?
No. Both require a consultation with a licensed provider. Legitimate routes are manufacturer-direct (NovoCare, LillyDirect) and telehealth providers. There are no compliant 'samples' of a prescription medication without a clinician.
What about compounded semaglutide or tirzepatide?
Compounded versions exist and are prepared by pharmacies, but they are not FDA-approved finished products, and the rules and availability change over time. If a provider offers a compounded version, confirm exactly what you're getting and the total price before enrolling.
Which one is more effective?
We don't make comparative efficacy claims — that's a clinical judgment a licensed provider makes for your situation. Both are FDA-approved prescription medications. Statements have not been evaluated by the FDA.